BRD4 and neuroblastoma: Since single agent treatments have thus far not provided the desired outcome benefit for high-risk neuroblastoma patients and since they can lead to acquired drug resistance, we also assessed the utility of a BRD4 inhibitor (JQ1) and CBP/p300 inhibitor (C646 and I-CBP112) combination.